The Voice of Canadians With Breast Cancer

Education

Educational Events

SHARE Cancer Support

Patient-Center Dosing for Individuals with MBC

Unlike patients with early stage breast cancer whose disease is potentially curable and whose treatment period is limited, most patients with MBC will remain in treatment for the rest of their lives.

Whenever they begin a new treatment, patients with MBC are generally prescribed the same drug dosage as early stage breast cancer patients. This dosage is often based upon the Maximum Tolerated Dose (MTD), which is the highest dose that will not cause unacceptable toxicity. Nevertheless, as a result of treatment-related side effects, many patients with MBC experience a considerably diminished quality of life.

Since most drugs for MBC are available in several dosages, the Patient-Centered Dosing Initiative (PCDI) is building a framework to help physicians and patients select the optimal dosage for the patient based upon their unique physical, circumstantial, and psychological factors. 

When:

July 28th
3PM to 4PM (ET)

Where:

ONLINE

Who:

  • Patients

  • Physicians

Key topics:

  • Help physicians and patients select the optimal dosage for the patient based upon their unique physical, circumstantial, and psychological factors

For more information and to register, click here.

SHARE

Financial
Navigator

Your path to accessing financial resources

Quick Find

Our Stories

Events

See our calendar